Myeloproliferative Diseases
11
2
2
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
27.3%
3 terminated out of 11 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
133%
8 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Investigation of the Genetics of Hematologic Diseases
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia